SCHEMBL20103304

SCHEMBL20103304

CCOC(=O)c1cncc(OCc2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
HTT P42858 1/20 0.54
GFER P55789 1/20 0.54
HSD17B10 Q99714 1/20 0.54
MAOB P27338 3/20 0.53
HSP90AA1 P07900 1/20 0.53
GABRA1 P14867 1/20 0.52
GABRG2 P18507 1/20 0.52
GABRB3 P28472 1/20 0.52
GABRA5 P31644 1/20 0.52
GABRA3 P34903 1/20 0.52
GABRA2 P47869 1/20 0.52
SIRT2 Q8IXJ6 5/20 0.50
SIRT3 Q9NTG7 4/20 0.50
SIRT1 Q96EB6 3/20 0.50
NMT1 P30419 2/20 0.50
LMNA P02545 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1202881 0.86 SIRT2 (0.59) KMT2AMEN1HTTGFERHSD17B10
SCHEMBL4400182 0.85 KMT2A (0.67) KMT2AMEN1MAOBHSP90AA1GABRA1
SCHEMBL16047593 0.85 MAOB (0.63) KMT2AMEN1MAOBHSP90AA1GABRA1
SCHEMBL31418011 0.84 MAOB (0.48) CYP2C9CYP2C19KMT2AMEN1MAOB
SCHEMBL27189439 0.83 MEN1 (0.56) KMT2AMEN1HTTGFERHSD17B10
SCHEMBL1201866 0.83 MEN1 (0.70) KMT2AMEN1HTTGFERHSD17B10
SCHEMBL30822583 0.83 MEN1 (0.70) KMT2AMEN1HTTGFERHSD17B10
SCHEMBL3862907 0.83 CYP2C9 (0.66) CYP2C9CYP2C19KMT2AMEN1LMNA
SCHEMBL340106 0.82 MAOB (0.69) KMT2AMEN1MAOBHSP90AA1NR4A2
SCHEMBL2197204 0.82 MEN1 (0.68) KMT2AMEN1HTTGFERHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10988433-B2 Cyclohexyl GPR40 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2021-04-27 US disclosed
US-20200039914-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN RESEARCH & DEVELOPMENT, LLC 2020-02-06 US disclosed
WO-2018081047-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039914-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES GPR119, GPR65, GPR55 CYP2C9 4604/4885CYP2C19 4507/4885KMT2A 3114/4885
US-10988433-B2 Cyclohexyl GPR40 agonists for the treatment of type II diabetes GPR119, GPR65, GPR55 CYP2C9 4604/4885CYP2C19 4507/4885KMT2A 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.